Avidity Biosciences Inc (RNA) USD0.0001
Sell:$27.50Buy:$33.04
$1.02
(3.17%)
Prices delayed by at least 15 minutes
- This stock can be held in a
Stocks and Shares ISASell:$27.50
Buy:$33.04
Change:$1.02
(3.17%)
$1.02
(3.17%)Prices delayed by at least 15 minutes
Sell:$27.50
Buy:$33.04
Change:$1.02
(3.17%)
$1.02
(3.17%)Prices delayed by at least 15 minutes
Director deals
Listed below are trades carried out by directors and other individuals which are required to be notified to the market.
Recent deals
| Date | Name and position (if held) | Deal type | Number of shares dealt | Price per share | Value of trade | Shares remaining |
|---|---|---|---|---|---|---|
| 11 March 2025 | W Michael FlanaganChief Level Officer | Sell Option/Award related | 20,000 | $30.13 | $602,614.00 | 91,975 |
| 3 March 2025 | Kathleen P GallagherChief Level Officer | Sell Option/Award related | 5,875 | $29.41 | $172,807.25 | 50,554 |
| 3 February 2025 | Kathleen P GallagherChief Level Officer | Sell Option/Award related | 5,875 | $32.16 | $188,918.26 | 50,554 |
| 22 January 2025 | Kathleen P GallagherChief Level Officer | Sell Regular sell transaction (market) | 5,629 | $30.16 | $169,775.71 | 50,554 |
| 21 January 2025 | Sarah BoycePresident/CEO | Sell Tax related | 4,738 | $28.59 | $135,474.58 | 343,070 |
| 21 January 2025 | Sarah BoycePresident/CEO | Sell Tax related | 5,659 | $28.59 | $161,816.84 | 337,411 |
| 21 January 2025 | Michael F. MacLeanCFO | Sell Tax related | 1,622 | $28.59 | $46,377.68 | 106,320 |
| 21 January 2025 | Teresa McCarthyGroup Director | Sell Tax related | 1,738 | $28.59 | $49,694.81 | 106,129 |
| 21 January 2025 | Teresa McCarthyGroup Director | Sell Tax related | 1,221 | $28.60 | $34,916.69 | 104,908 |
| 21 January 2025 | Michael F. MacLeanCFO | Sell Tax related | 1,665 | $28.59 | $47,607.68 | 104,655 |
5 most significant deals
| Date | Name and position (if held) | Deal type | Number of shares dealt | Price per share | Value of trade | Shares remaining |
|---|---|---|---|---|---|---|
| 13 June 2024 | Sarah BoycePresident/CEO | Sell Option/Award related | 164,233 | $40.08 | $6,581,801.71 | 112,117 |
| 12 June 2024 | Michael F. MacLeanCFO | Sell Option/Award related | 104,245 | $35.72 | $3,723,141.45 | 44,093 |
| 12 June 2024 | Sarah BoycePresident/CEO | Sell Option/Award related | 100,000 | $35.73 | $3,573,020.00 | 112,117 |
| 1 October 2024 | W Michael FlanaganChief Level Officer | Sell Option/Award related | 62,500 | $47.62 | $2,976,112.50 | 85,389 |
| 6 November 2024 | Michael F. MacLeanCFO | Sell Option/Award related | 65,182 | $45.33 | $2,954,954.27 | 94,093 |
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Director deal information provided by Factset.